Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Friday broker round-up UPDATE

Fri, 01st Aug 2014 10:33

AstraZeneca: Deutsche Bank ups target price from 3950p to 4000p staying with its hold recommendation.Avacta: Numis places both its target price and its buy recommendation under review.Barclays: Berenberg upgrades from sell to hold with a target price of 220p.Bodycote: UBS shifts target price from 860p to 865p and maintains a buy recommendation.Breedon: Berenberg initiates with a target price of 50p and a buy recommendation.Capita: Credit Suisse lowers target price from 1250p to 1215p and downgrades from outperform to neutral.Computacenter: Jefferies cuts target price from 720p to 690p retaining a hold recommendation.CVS Group: Berenberg starts with a target price of 410p and a buy recommendation.Daily Mail & General Trust: Numis shifts target price from 1180p to 1185p and stays with its buy recommendation.Diageo: Canaccord Genuity reduces target price from 1835p to 1540p downgrading from hold to sell.Dignity: Berenberg initiates with a target price of 1600p and a buy recommendation.Hikma Pharmaceuticals: Jefferies moves target price from 1600p to 1610p and keeps a hold recommendation.IMI: Investec places its target price (prev.: 1570p) under review, while leaving its buy recommendation unchanged.Informa: Goldman Sachs ups target price from 527p to 550p upgrading from sell to neutral.Intu Properties: Deutsche Bank moves target price from 270p to 280p and maintains a hold recommendation.Lancashire Holdings: Credit Suisse reduces target price from 800p to 680p, while leaving its outperform rating unaltered.Lloyds Banking Group: Deutsche Bank shifts target price from 87p to 89p and keeps a buy recommendation.Man Group: Panmure Gordon downgrades from buy to hold with a target price of 125p.Micro Focus: Jefferies raises target price from 420p to 635p, while maintaining an underperform rating.Next: Berenberg raises target price from 7740p to 8075p maintaining a buy recommendation.Parkmead: Numis initiates with a target price of 262p and a buy recommendation.Pennon Group: Credit Suisse moves target price from 645p to 655p and reiterates an underperform rating.PZ Cussons: Panmure Gordon moves target price from 400p to 410p retaining a buy recommendation.Randgold Resources: UBS downgrades from buy to neutral with a target price of 5400p. RBC Capital reduces target price from 5300p to 5200p and stays with a neutral rating.Rightmove: Jefferies reduces target price from 2260p to 2177p keeping a hold recommendation.Rolls-Royce Group: Deutsche Bank cuts target price from 900p to 860p retaining its sell recommendation.Royal Bank of Scotland: Investec ups target price from 325p to 340p, while downgrading from hold to sell.Royal Dutch Shell: Jefferies increases target price from 2460p to 2730p upgrading from hold to buy. UBS raises target price from 2300p to 2450p staying with its neutral rating.RPS Group: Jefferies reduces target price from 385p to 320p, while leaving its buy recommendation unchanged.Schroders: Jefferies raises target price from 2300p to 2500p and reiterates a hold recommendation. Numis cuts target price from 3087p to 3042p retaining its buy recommendation.SDL: Jefferies reduces target price from 620p to 480p, while keeping a buy recommendation.Severn Trent: Credit Suisse increases target price from 1540p to 1730p upgrading to neutral.Smith & Nephew: Investec downgrades from buy to add with a target price of 1100p.UBM: Canaccord Genuity cuts target price from 725p to 680p and retains a hold recommendation.United Utilities: Credit Suisse raises target price from 680p to 730p, while downgrading to underperform.Vesuvius: Investec places both its target price (prev.: 465p) and its add rating under review.Weir Group: Morgan Stanley raises target price from 2440p to 2510p and keeps an equal-weight rating.Zoopla Property: Jefferies initiates with a target price of 325p and a buy recommendation.

Related Shares

More News
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of no...

10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's lat...

10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but abo...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.